Click here to close now.

Welcome!

News Feed Item

Veloxis Pharmaceuticals publishes Annual Report 2013

HORSHOLM, Denmark, March 5, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2013. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

This company announcement should be read in conjunction with Veloxis' annual report 2013 published separately today.

Full Year 2013 Highlights

  • Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® for the prevention of organ rejection in kidney transplant recipients.
  • Granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
  • Dosing of the first patient in ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients. The ASERTAA study is designed to compare the pharmacokinetics (PK) of Envarsus®, a once-daily tacrolimus tablet, to generic twice daily tacrolimus capsules in stable African-American renal transplant patients.
  • The trade name for LCP-Tacro™ is Envarsus®.
  • Envarsus® successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints.
  • The European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014.
  • Data from the STRATO study demonstrates the potential for Envarsus® to improve tacrolimus-induced tremors in stable kidney transplant patients.
  • Submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in kidney transplant patients in the European Union.
  • During 2013, Veloxis recognized deferred revenue of DKK 38.2 million as revenue compared to DKK 6.9 million in 2012. Deferred revenue consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. and is recognized in the income statement based on planned development periods.
  • Research and development costs decreased by DKK 64.2 million, or by 30.5%, from DKK 210.7 million in 2012 to DKK 146.5 million in 2013. Research and development costs are mainly attributable to the phase III trial in Envarsus® (de novo patients, Study 3002). The reduction in cost between the two periods is mainly related to effect from the executed restructuring and discontinuation of other pipeline activities in May 2012.
  • Administrative expenses decreased by DKK 9.1 million or by 24.7%, from DKK 36.9 million in 2012 to DKK 27.8 million in 2013. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the reduction in the number of employees that took place in May 2012.
  • During 2013, Veloxis recognized DKK 139.3 million in net loss compared to DKK 262.7 million in 2012. The net loss is better than management's expectations for 2013 as reported on 13 November 2013 in connection with the third quarter interim report, which projected a net loss of DKK 160 - 190 million. The positive deviation is mainly driven by the granted orphan drug status which has reduced regulatory costs.
  • As per 31 December 2013, the balance sheet reflects cash and cash equivalents of DKK 328.7 million compared to DKK 496.8 million as per 31 December 2012. The decrease in cash position reflects the changes in operating activities in 2013. The cash position is in line with management's expectations for 2013, which projected a cash position at the end of 2013 of DKK 310 - 340 million.

Conference Call
On 5 March, 2014, Veloxis' Management will host a conference call, at 2:00 PM CET (Denmark); 1:00 PM GMT (London), 8:00 AM ET (New York).

To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 Denmark
+44 (0) 1452 555 131 UK
+1 866 682 8490 USA
Access code 1728236

Following the conference call, a recording will be available on the company's website www.veloxis.com. A presentation will be available on Veloxis' website (under 'Investors').


 


Financial Highlights













DKK'000

2013

2012

2011

2010

2009








Income Statement






Revenue

38,148

6,868

-

1,496

2,476

Research and development costs

(146,512)

(210,739)

(222,053)

(210,426)

(210,140)

Administrative expenses

(27,771)

(36,889)

(47,814)

(52,198)

(62,381)

Operating loss before restructuring cost

(136,135)

(240,760)

(269,867)

(261,128)

(270,045)

Restructuring cost

-

(21,462)

-

(10,894)

(9,489)

Operating loss

(136,135)

(262,222)

(269,867)

(272,022)

(279,534)

Net financial income / (expenses)

(4,426)

(850)

16,048

(759)

8,540

Loss before tax

(140,561)

(263,072)

(253,819)

(272,781)

(270,994)

Tax for the period

1,250

363

1,193

(1,425)

-

Net loss for the period

(139,311)

(262,709)

(252,626)

(274,206)

(270,994)








Balance Sheet






Cash and cash equivalents

328,652

496,834

297,727

531,519

333,429

Total assets

348,863

509,271

320,927

562,906

379,269

Share capital

166,057

165,932

452,543

452,543

56,568

Total equity

279,042

409,737

255,900

498,238

317,281

Investment in property, plant and equipment

1,055

260

2,981

2,583

11,043








Cash Flow Statement






Cash flow from operating activities

(157,747)

(205,870)

(234,637)

(238,148)

(251,158)

Cash flow from investing activities

(1,055)

169,712

(169,778)

(2,658)

(11,011)

Cash flow from financing activities

(3,227)

404,304

(5,948)

440,014

729

Cash and cash equivalents at period end

328,652

496,834

297,727

531,519

333,429








Financial Ratios






Basic and diluted EPS (DKK)

(0.08)

(0.43)

(0.56)

(2.84)

(4.80)

Weighted average number of shares

1,660,353,248

607,511,489

452,542,480

96,707,708

56,443,701

Average number of employees (FTEs)

26

48

52

59

93

Assets/equity

1.25

1.24

1.25

1.13

1.20

 

Fourth Quarter 2013 Highlights

  • Research and development cost were realized at DKK 29.5 million compared to DKK 41.9 million in same period in  2012, and DKK 35.2 million in the previous quarter.
  • Administrative expenses were realized at DKK 6.5 million compared to DKK 10.2 million in same period in 2012, and DKK 6.7 million in the previous quarter.
  • Operating loss amounted to DKK 23.8 million, while net loss was realized at DKK 24.7 million.

Financial Highlights








Quarterly Numbers in DKK




















Q4

Q3

Q2

Q1

Q4

Q3

Q2

Q1



2013

2013

2013

2013

2012

2012

2012

2012



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Income Statement









Revenue

12,206

12,206

6,868

6,868

6,868

-

-

-

Research and development costs

(29,546)

(35,247)

(42,772)

(38,947)

(41,890)

(49,362)

(56,639)

(62,848)

Administrative expenses

(6,457)

(6,703)

(6,834)

(7,777)

(10,235)

(6,961)

(9,462)

(10,231)

Operating loss before restructuring cost

(23,797)

(29,744)

(42,738)

(39,856)

(45,257)

(56,323)

(66,101)

(73,079)

Restructuring cost

-

-

-

-

-

-

(21,462)

-

Operating loss

(23,797)

(29,744)

(42,738)

(39,856)

(45,257)

(56,323)

(87,563)

(73,079)

Net financial income / (expenses)

(1,425)

(4,655)

(2,253)

3,907

(2,302)

993

2,051

(1,592)

Loss before tax

(25,222)

(34,399)

(44,991)

(35,949)

(47,559)

(55,330)

(85,512)

(74,671)

Tax for the period

522

242

241

244

1,034

(223)

(130)

(318)

Net loss for the period

(24,700)

(34,157)

(44,750)

(35,704)

(46,525)

(55,553)

(85,642)

(74,989)











Balance Sheet









Cash and cash equivalents

328,652

380,179

399,743

456,216

496,834

86,683

152,720

213,786

Total assets

348,863

388,982

409,371

465,939

509,271

99,590

167,799

235,187

Share capital

166,057

166,057

166,057

166,057

165,932

45,254

45,254

452,543

Total equity

279,042

302,307

334,686

377,276

409,737

42,103

98,968

182,545

Investment in property,









plant and equipment

1,055

-

-

-

43

-

126

91











Cash Flow Statement









Cash flow from operating activities

(47,417)

(14,040)

(51,165)

(45,125)

(399)

(62,707)

(62,400)

(80,364)

Cash flow from investing activities

(1,055)

-

-

-

56,619

59,486

24,174

29,433

Cash flow from financing activities

(319)

(401)

(2,555)

48

410,149

(3,450)

(1,085)

(1,310)

Cash and cash equivalents









at period end

328,652

380,179

399,743

456,216

496,834

86,683

152,720

213,786











Financial Ratios









Basic and diluted EPS

(0.01)

(0.02)

(0.03)

(0.02)

(0.08)

(0.12)

(0.19)

(0.17)

Weighted average number of shares

1,660,572,426

1,660,572,426

1,660,572,426

1,659,683,537

607,511,489

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

23

26

27

29

33

49

55

55

Assets/equity

1.25

1.29

1.22

1.24

1.24

2.37

1.70

1.29

Outlook for 2014
Veloxis is expecting an operating loss of DKK 60 - 90 million compared to the realized operating loss of DKK 136 million in 2013. Net loss is expected to be in the range of DKK 55 - 85 million compared to the net loss of DKK 139 million in 2013. As of 31 December 2013, the Company's cash position equaled DKK 329 million and the Company's 31 December 2014 cash position is expected to be in the range of DKK 230 - 270 million.

The above estimates are subject to possible changes primarily due to the timing of regulatory approvals and associated milestone payments along with variation of clinical activities and fluctuating exchange rates.

Important events following the balance sheet date
On 8 January, Veloxis announced that United States Patent and Trademark Office had issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus®.

For more information, please contact:

Veloxis Pharmaceuticals A/S




John D. Weinberg

Executive Vice President & CCO

Mobile: +1 732 321 3208

Email: [email protected]  

Johnny Stilou

Executive Vice President & CFO

Phone: + 45 21 227 227

Email: [email protected]

About Envarsus® and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. Envarsus® is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit www.veloxis.com.

SOURCE Veloxis Pharmaceuticals

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In the midst of the widespread popularity and adoption of cloud computing, it seems like everything is being offered “as a Service” these days: Infrastructure? Check. Platform? You bet. Software? Absolutely. Toaster? It’s only a matter of time. With service providers positioning vastly differing offerings under a generic “cloud” umbrella, it’s all too easy to get confused about what’s actually being offered. In his session at 16th Cloud Expo, Kevin Hazard, Director of Digital Content for SoftL...
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies drivi...
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at DevOps Summit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
Malicious agents are moving faster than the speed of business. Even more worrisome, most companies are relying on legacy approaches to security that are no longer capable of meeting current threats. In the modern cloud, threat diversity is rapidly expanding, necessitating more sophisticated security protocols than those used in the past or in desktop environments. Yet companies are falling for cloud security myths that were truths at one time but have evolved out of existence.
The cloud has transformed how we think about software quality. Instead of preventing failures, we must focus on automatic recovery from failure. In other words, resilience trumps traditional quality measures. Continuous delivery models further squeeze traditional notions of quality. Remember the venerable project management Iron Triangle? Among time, scope, and cost, you can only fix two or quality will suffer. Only in today's DevOps world, continuous testing, integration, and deployment upend...
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
To many people, IoT is a buzzword whose value is not understood. Many people think IoT is all about wearables and home automation. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed some incredible game-changing use cases and how they are transforming industries like agriculture, manufacturing, health care, and smart cities. He will discuss cool technologies like smart dust, robotics, smart labels, and much more. Prepare...
"We provide a web application framework for building really sophisticated web applications that run on a browser without any installation need so we get used for biotech, defense, and banking applications," noted Charles Kendrick, CTO and Chief Architect at Isomorphic Software, in this SYS-CON.tv interview at @DevOpsSummit (http://DevOpsSummit.SYS-CON.com), held June 9-11, 2015, at the Javits Center in New York
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...